Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Trial Profile

A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2018

At a glance

  • Drugs Lacritin (Primary)
  • Indications Dry eyes; Sjogren's syndrome
  • Focus Therapeutic Use
  • Sponsors TearSolutions
  • Most Recent Events

    • 08 Aug 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
    • 08 Aug 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jun 2019.
    • 28 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top